Genmab A/S
CSE:GMAB
Genmab A/S
Total Equity
Genmab A/S
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Genmab A/S
CSE:GMAB
|
Total Equity
kr36.7B
|
CAGR 3-Years
18%
|
CAGR 5-Years
21%
|
CAGR 10-Years
34%
|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Total Equity
kr8.6B
|
CAGR 3-Years
110%
|
CAGR 5-Years
47%
|
CAGR 10-Years
42%
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Total Equity
-€105.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Total Equity
kr11.4B
|
CAGR 3-Years
16%
|
CAGR 5-Years
44%
|
CAGR 10-Years
25%
|
|
|
Bioporto A/S
CSE:BIOPOR
|
Total Equity
kr67.8m
|
CAGR 3-Years
14%
|
CAGR 5-Years
22%
|
CAGR 10-Years
9%
|
|
|
Saniona AB
STO:SANION
|
Total Equity
kr231.8m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
34%
|
CAGR 10-Years
39%
|
|
Genmab A/S
Glance View
In the world of biotechnology, Genmab A/S has carved a niche as a leader in the development and innovation of antibody therapeutics. Established in Denmark in 1999, the company has focused on harnessing the power of antibodies to create novel treatments for cancer and other serious diseases. Genmab's approach is both scientific and strategic, leveraging its proprietary DuoBody and HexaBody platforms to engineer antibodies that are designed to enhance effectiveness and reduce side effects. This innovative focus has not only set Genmab apart as a pioneer in immunotherapy but has also yielded a rich pipeline of products, several of which have gained regulatory approval and found a place in global markets. Genmab's business model is built on a foundation of collaboration and strategic partnerships with major pharmaceutical companies, including heavyweights such as Janssen and Roche. These alliances are crucial as they provide the financial support needed for large-scale clinical trials and access to global distribution networks. Revenue streams primarily flow from milestone payments, licensing fees, and royalties generated from successful therapies. The company's notable blockbuster, Darzalex, a treatment for multiple myeloma, continues to be a significant revenue driver, exemplifying Genmab's capacity to transform scientific discovery into economic success. Through this blend of innovation, strategic partnerships, and commercialization, Genmab maintains a robust business while keeping its dedication to pioneering treatments at the forefront of its mission.
See Also
What is Genmab A/S's Total Equity?
Total Equity
36.7B
DKK
Based on the financial report for Dec 31, 2024, Genmab A/S's Total Equity amounts to 36.7B DKK.
What is Genmab A/S's Total Equity growth rate?
Total Equity CAGR 10Y
34%
Over the last year, the Total Equity growth was 16%. The average annual Total Equity growth rates for Genmab A/S have been 18% over the past three years , 21% over the past five years , and 34% over the past ten years .
You don't have any saved screeners yet